ECRM Generics 2008

It’s apparent that the pharmaceutical landscape continues to be dominated by major brand-name drugs losing patent protection and a flurry of generic launches aimed at taking whatever share of the market they can. That’s good news and bad news for pharmacy retailers; good in that the generic introductions are expected to drive huge profit gains during their initial 180-day exclusivity period, bad in that prices tend to fall away quite dramatically in the period thereafter due to the increased competition that results, depressing top-line sales growth.

Click below to download the PDF of "ECRM Generics."